Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03207087
Other study ID # CP-16-001
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date June 21, 2017
Est. completion date April 30, 2021

Study information

Verified date October 2020
Source Sequent Medical, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial is a prospective, multicenter, single-arm confirmatory clinical trial. The study is to confirm the safety and effectiveness of the WEB Aneurysm Embolization System demonstrated in the US WEB-IT Study for the treatment of intracranial wide-neck bifurcation aneurysms. The study's primary endpoints include a primary effectiveness endpoint and a primary safety endpoint. The study device must meet both endpoints. The primary effectiveness endpoint is adjudicated by an independent third party core lab.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 60
Est. completion date April 30, 2021
Est. primary completion date January 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patient whose age = 18 and =75 years old - Patient must have a single ruptured or unruptured IA(intracranial aneurysm)requiring treatment - Patient must sign and date IRB/EC approved written informed consent prior to initiate of any study procedures Exclusion Criteria: - Patient has an IA with characteristics unsuitable for endovascular treatment - Patient has stroke-in-evolution within the prior 60-days - Patient has had an SAH(subarachnoid hemorrhage) from a nonindex IA or any other intracranial hemorrhage within 90 days - Patient's index IA was previously treated - Patient is pregnant

Study Design


Related Conditions & MeSH terms


Intervention

Device:
WEB Aneurysm Embolization
Subjects will be screened for study eligibility after giving informed consent. The WEB embolization procedure will be performed in the catheterization room using standard angiographic techniques.

Locations

Country Name City State
China Tiantan Hospital Beijing
China Xuanwu Hospital, Capital Medical University Beijing
China West China Chengdu Sichuan
China The Second affiliated Hospital of Zhejiang University School of Medicine Hangzhou
China Changhai Hospital Affiliated to The Second Military Medical University ( Shanghai Changhai Hospital) Shanghai Shanghai
China Huashan Hospital Shanghai
China The General Hospital of Shenyang Military Shenyang
China Tangdu Hospital, the Fourth Military Medical University Xi'an

Sponsors (1)

Lead Sponsor Collaborator
Sequent Medical, Inc

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Effectiveness Endpoint: Complete (angiographic) aneurysm occlusion as assessed by Core Lab, without parent artery stenosis Proportion of complete (angiographic) aneurysm occlusion as assessed by Core Lab without retreatment, recurrent subarachnoid hemorrhage, without significant parent artery stenosis (>50% stenosis) at one year after treatment. 12 month
Primary Primary Safety Endpoint: Proportion of death and major stroke Proportion of death of any nonaccidental cause or any major stroke (defined as an ischemic or hemorrhagic stroke resulting in an increase of 4 points or more on the National Institutes of Health Stroke Scale) within the first 30 days after treatment or major ipsilateral stroke or death due to neurologic cause from day 31 to the 1 year after treatment. 12 month
See also
  Status Clinical Trial Phase
Recruiting NCT04839705 - Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device N/A
Active, not recruiting NCT02191618 - The WEB-IT Clinical Study N/A